INTRODUCTION
♦ Psoriasis is a chronic, inflammatory disorder with a predisposing genetic component, predominantly affecting the skin. Psoriasis is estimated to affect around 1.3-2.2% of the UK population 1 and the most common type is plaque psoriasis, affecting 80-90% of psoriasis patients 2 ♦ As psoriasis treatment options have recently expanded to include biologics ixekizumab and secukinumab, as well as apremilast (a novel small molecule), there is a need to model sequential treatment to reflect clinical practice of cycling through different treatment modalities ♦ This study aimed to estimate the cost-effectiveness of sequential treatment with biologics in the United Kingdom (UK) incorporating ixekizumab and secukinumab treatments
METHODS
♦ A de novo Markov model was constructed using monthly cycles and four health states: trial (tunnel state), maintenance, best supportive care (BSC) and death ♦ Comparison of an ixekizumab sequence (ixekizumab 80mg -ustekinumab 90mg -infliximab 5mg/kg -BSC) against a secukinumab sequence (secukinumab 300mg -ustekinumab 90mg -infliximab 5mg/kg -BSC), following EMA label dosing regimens for all drugs, and using list price as both ixekizumab and secukinumab had a confidential PAS approved price ♦ At the end of the trial period (10 weeks for infliximab, 12 weeks for all other treatments), responders (defined as PASI≥75) are transitioned to maintenance therapy; non-responders (PASI<75) move directly to the trial period of the next treatment in the sequence ♦ In line with previous economic evaluations [3] [4] and supported by long-term registry data 5 , all-cause discontinuation during the maintenance period was set at 20% annually for all treatments, and discontinuing patients were transitioned to the trial period of the next therapy in the sequence; responders are assumed to maintain response until discontinuation ♦ After failure of the third line biologic, patients were transitioned to BSC ♦ Modeling efficacy: PASI response rates informing the transition from trial to maintenance period were derived from a network meta-analysis using a random effects Bayesian model for multi-arm trials with a multinomial likelihood and probit link ♦ Discounting: 3.5% for costs and effects in line with the NICE reference case 6 ♦ Mortality: Gender-specific mortality rates obtained from the Human Mortality Database for the UK 7 ,and weighted according to the proportion of males (68%) in the UNCOVER-1, 2 and 3 trials ♦ Quality of life: Utility gains from baseline to week 12 for each PASI response state (PASI<50, PASI 50-74, PASI 75-89, PASI 90-99 and PASI 100) were estimated from baseline to week 12 using a regression model of EQ-5D-5L data from the DLQI>10 population of the ixekizumab studies, using the England value set and adjusted for baseline EQ-5D-5L 8 ♦ Costs and resource use: Drug list prices were obtained from MIMs 9 ; resource use associated with biologic treatments was obtained from NICE clinical guidelines 10 . The cost of BSC was taken from a published UK study 11 and inflated to 2015 ♦ Non-responders: An additional cost for non-responders, calculated from the costs incurred 12 months prior to biologic initiation minus outpatient visits reported by Fonia et al. 11 , was applied to the trial period following a treatment failure, based on the recommendations from the ERG in the final appraisal determination for apremilast 3
RESULTS (CONT.)
♦ Over a lifetime time horizon, the ixekizumab sequence resulted in cost-savings of £943 and gained 0.03 more QALYs in comparison to the secukinumab sequence ♦ Differences in costs and QALYs between the arms reflect the difference in time spent in the treatment and BSC health states ♦ Probabilistic sensitivity analysis -PSA of 5000 iterations was run comparing the two sequences. 70% of the observations were in the south-east quadrant (less costly with higher QALY gains), and 27% in the northeast quadrant (more costly with higher QALY gains).
Ixekizumab sequence Secukinumab sequence Difference
♦ At a willingness-to-pay (WTP) of £0, the ixekizumab sequence had a 70% probability of being cost-effective, increasing to over 90% probability of being cost-effective at £22,000
CONCLUSIONS
♦ The model demonstrated that, while using list prices, ixekizumab as a first-line treatment in a biologic sequence dominates secukinumab, providing higher QALYs at lower cost ♦ When running deterministic and probabilistic sensitivity analyses, the findings indicated that the model was robust in its results ♦ Sequential modelling approach was chosen to reflect clinical practice of treatment in psoriasis ♦ Limitations of this study include: treatment responders are assumed to maintain response until discontinuation, all-cause discontinuation rate is assumed to be equal for all comparators and constant throughout the maintenance period, no effect modification is applied for patients with prior biologic use, and the use of list prices rather than confidential UK PAS prices ♦ One-way sensitivity analysis-model indicated that the most sensitive parameters were drug costs for ixekizumab and secukinumab, and proportion of patients who achieve PASI75 response 
